INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
Adrenal suppression: A practical manual for diagnosing and treating this under-esteemed side effect of inhaled corticosteroid in an asthmatic patient
Authors Name:
Mr Basharat Nawaz
, Mr. Mohd Razi , Mrs Aliya Rehmani , Mrs Binita Ghosh , Mr Akhilesh Patel
Unique Id:
IJSDR2303186
Published In:
Volume 8 Issue 3, March-2023
Abstract:
Asthma remains one of the most common chronic respiratory diseases. It is estimated that approximately 300 million people of all ages and all ethnic backgrounds suffer from asthma and the burden related to this disease to governments and health care systems. The WHO (World Health Organization) has estimated that 15 million disability-adjusted life years are lost annually, and 250000 asthma deaths are reported worldwide. For the treatment of asthma, inhaled corticosteroids (ICSs) are the most effective anti-inflammatory drugs currently on the market. Inhaled corticosteroids are now widely accepted as a first-line preventive treatment in asthma increasing use is being made of high-dose inhaled corticosteroids during the step-up phase of treatment in order to optimize asthma control. Side effects of ICSs are adrenal insufficiency, a disorder known as adrenal insufficiency that occurs when the adrenal glands are unable to generate enough cortisol. It results from either deficiency or impaired action of glucocorticoids. Adrenal insufficiency (AI) is a life-threatening disorder that can result from primary adrenal failure or secondary adrenal disease due to impairment of the hypothalamic-pituitary-adrenal (HPA) axis. Typical symptoms of AI include weakness, fatigue, anorexia, abdominal pain, weight loss and salt craving. The risk-to-benefit ratio for inhaled corticosteroids comprises their relative potencies for airway and systemic glucocorticoid activity. Fluticasone propionate (hereafter fluticasone) and budesonide are inhaled corticosteroids used for asthma. It is generally accepted that fluticasone propionate is at least twice as potent as budesonide.
"Adrenal suppression: A practical manual for diagnosing and treating this under-esteemed side effect of inhaled corticosteroid in an asthmatic patient", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.8, Issue 3, page no.1125 - 1134, March-2023, Available :http://www.ijsdr.org/papers/IJSDR2303186.pdf
Downloads:
000336257
Publication Details:
Published Paper ID: IJSDR2303186
Registration ID:204731
Published In: Volume 8 Issue 3, March-2023
DOI (Digital Object Identifier):
Page No: 1125 - 1134
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn